George Melnik, MD
Otolaryngology · Valparaiso, INNPI 1265403018
Payments from drug & device makers
Across 29 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$156
- Intersect ENT, Inc.$146
- Regeneron Healthcare Solutions, Inc.$118
- Sanofi$95
- GSK$51
- Integra Lifesciences Corporation$19
- plus $62 from 4 others
What the payments were for
- Food & beverage$649100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 8 | $156 |
| Intersect ENT, Inc. | 5 | $146 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Sanofi | 4 | $95 |
| GSK | 2 | $51 |
| Integra Lifesciences Corporation | 1 | $19 |
| Acclarent, Inc | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Aerin Medical Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
How this compares
$649 in reported general payments places this provider in the 30th percentile of 193 otolaryngology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 22 | $94,925 |
| Olopatadine Hcl | 537 | $40,321 |
| Ipratropium Bromide | 533 | $11,662 |
| Mometasone Furoate | 128 | $9,633 |
| Omeprazole | 374 | $7,122 |
| Fluocinolone Acetonide Oil | 169 | $7,070 |
| Levocetirizine Dihydrochloride | 788 | $6,849 |
| Doxycycline Monohydrate | 181 | $6,656 |
| Fluticasone Propionate | 386 | $5,103 |
| Azelastine Hcl | 186 | $4,535 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 23 | $2,376 |
| Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid | 11 | $2,189 |
| Cevimeline Hcl | 11 | $2,130 |
| Montelukast Sodium | 288 | $2,019 |
| Pantoprazole Sodium | 106 | $1,168 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Valparaiso
- Scott PhillipsCarmel$2.2M
- Joshua GreeneAnderson$1.1M
- Venkata KakarlapudiNew Albany$175K
- Colin NeumannNew Albany$135K
- Noah ParkerCarmel$133K
- Tod HuntleyCarmel$124K
- Satyan SreenathIndianapolis$103K
- Benjamin AnthonyIndianapolis$55K
- Eric CarterNew Albany$52K
- Daniel VinhIndianapolis$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.